Home › NDC Lookup › RxCUI directory › RxCUI 2704012

Hydrochlorothiazide 800 MG Powder for Oral Suspension — RxCUI 2704012

RxNorm drug concept · Semantic clinical drug
RxCUI 2704012 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2704012
Official nameHydrochlorothiazide 800 MG Powder for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asHCTZ 800 MG Powder for Oral Suspension; hydroCHLOROthiazide 800 MG (10 MG/mL) Powder for Oral Suspension
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)341 prescriptions · 14 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Hydrochlorothiazide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It lowers high blood pressure, which helps reduce the risk of strokes and heart attacks. Some products, such as Inzirqo and the tablets, are also used for swelling from conditions...
  • Take it by mouth exactly as prescribed, usually once a day. For swelling, your prescriber may have you take it only some days of the week. Food slightly lowers absorption, so ask m...
  • Dizziness, lightheadedness when standing, stomach upset, headache and weakness are the usual ones. Stand up slowly, and be careful with alcohol since it can worsen dizziness. Use s...
  • Call for eye pain or sudden vision changes, severe rash or blistering, trouble breathing, severe stomach pain, yellow skin or eyes, or unusual bruising or infections. Also call for...
📖 Read our full Hydrochlorothiazide guide →

🕸️ Concept Web — How Hydrochlorothiazide 800 MG Powder for Oral Suspe... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Hydrochlorothiazide 800 MG Powder for Oral Suspension RxCUI 2704012

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Hydrochlorothiazide 5487
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Inzirqo 2704013
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hydrochlorothiazide Powder for Oral Suspension 2704011
    • Hydrochlorothiazide Oral Powder Product 2704010
    • Hydrochlorothiazide Oral Product 1162786
    • Hydrochlorothiazide Powder for Oral Suspension [Inzirqo] 2704017
    • Inzirqo Oral Powder Product 2704016
    • Inzirqo Oral Product 2704015
    • Powder for Oral Suspension 1540456
    • Oral Powder Product 1294711
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Hydrochlorothiazide 800 MG SCDC · 2704009
  • Hydrochlorothiazide Powder for Oral Suspension SCDF · 2704011
  • Hydrochlorothiazide Oral Powder Product SCDG · 2704010
  • Hydrochlorothiazide Oral Product SCDG · 1162786

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2704012 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70954-0522-10 80 mL in 1 BOTTLE (70954-522-10) INZIRQO ANI Pharmaceuticals, Inc. 2025-01-30
Observed labelers: ANI Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$4.4599
Range $4.4599–$4.4599 · middle 50% $4.4599–$4.4599 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.